CO-LOCATED EVENTS
NextPrevious

Session

Case Study

Montag, 30. September

12:15 - 12:45

Live in Berlin

Weniger Details

While managing tail spend is relatively straightforward with major vendors like Oracle or Microsoft, the landscape shifts drastically when dealing with smaller vendors. Despite smaller budgets, the administrative workload remains substantial, demanding equal time and effort. In this session, you will explore essential principles and techniques for controlling tail spend in your organization and understand the critical importance of managing it effectively, regardless of vendor size.

  • Master the principles and techniques for controlling the tail spend
  • Explore the potential consequences of overlooking tail spend management
  • Implement strategies to efficiently reduce and streamline tail spend, optimizing overall procurement processes.

Sprecher

Dmitrij Subenko

Global Category Manager - IT Services, Novartis

Dmitrij has vast experience in procurement (sourcing, category management, contracting, P2P) both in NON-IT and IT area with the focus on IT services, software, hardware, cybersecurity, telecom and has been working in procurement in multinational financial, industrial and pharmaceutical companies in Europe. He has experience in building of procurement function from scratch and in development and improvement in mature organizations.

"In my job I love combination of data analysis and communication with people. There is always something new, it`s not routine job. And one of the main motivators is that I can see the result of my job and my effort.
There is always something you can learn from the partners, from suppliers, from colleagues, from the clients. And of course you can contribute a lot to the joint effort. In fact, procurement is not just a back office/support function. Procurement has direct impact on P&L, on the final product and services and on customers` satisfaction."

Unternehmen

Novartis

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide.

NextPrevious